GlaxoSmithKline | GSK - Current Assets



GlaxoSmithKline reported GBP17.67B in Current Assets for its fiscal quarter ending in June of 2025.


Current Assets Change Date
AbbVie USD 27.68B 2.09B Mar/2025
Alcon AG USD 6.31B 239M Jun/2025
Almirall EUR 714.05M 50.55M Jun/2025
Amgen USD 26.73B 195M Jun/2025
argenx SE 5.83B 946.64M Jun/2025
AstraZeneca USD 28.94B 2.8B Jun/2025
Bayer EUR 33.75B 1.08B Jun/2025
Biogen USD 7.97B 341.7M Jun/2025
Bristol-Myers Squibb USD 33.22B 2.44B Jun/2025
Eli Lilly USD 49.85B 8.59B Jun/2025
Fresenius EUR 10.88B 1.03B Jun/2025
Fresenius Medical Care EUR 8.14B 178.09M Jun/2025
Galapagos EUR 3.26B 217.04M Jun/2025
Genmab DKK 3.91B 127M Jun/2025
Gilead Sciences USD 14.72B 2.18B Jun/2025
GlaxoSmithKline GBP 17.67B 412M Jun/2025
Glaxosmithkline GBP 17.67B 676M Jun/2025
GRIFOLS EUR 5.25B 393.8M Jun/2025
Hikma Pharmaceutical USD 2.26B 22M Dec/2024
Lonza CHF 5.44B 113M Dec/2024
Merck EUR 12.2B 216M Jun/2025
Merck USD 37.07B 1.56B Jun/2025
Novartis USD 25.94B 831M Jun/2025
Novo Nordisk 162.71B 11.69B Jun/2025
Orion EUR 1.01B 76.5M Jun/2025
Pfizer USD 43.7B 2.16B Jun/2025
Philips EUR 9.06B 394M Jun/2025
Recordati EUR 1.57B 3.62M Jun/2025
Regeneron Pharmaceuticals USD 16.86B 712.2M Jun/2025
Roche Holding CHF 40.04B 6.41B Dec/2024
Sanofi 37.02B 7B Jun/2025
Smith & Nephew USD 4.63B 206M Jun/2025
UCB EUR 4.79B 1.47B Dec/2024